# Trust & Completeness Pass — Batch 2 and Completion Report

Date: 2026-07-15

Status: Applied
Branch: `agent/trust-completeness-batch-2`

## Outcome

Batch 2 completed the remaining 25 safety-reviewed compound profiles. All 50 profiles in the audited queue now publish their reviewed safety evidence through the existing `runtime_safety` field with a concise evidence-strength label, a separate “Who should avoid this?” summary, and conditional healthcare-provider guidance.

The trust audit reports 50 of 50 complete, zero remaining profiles, and zero validation errors. The safety audit remains at zero actionable full-public gaps.

## Compounds completed in Batch 2

1. `11-keto-beta-boswellic-acid`
2. `acemannan`
3. `acetyl-11-keto-beta-boswellic-acid`
4. `alpha-asarone`
5. `alpha-mangostin`
6. `ashitaba-extract`
7. `atractylenolide-i`
8. `atractylenolide-ii`
9. `atractylenolide-iii`
10. `aucubin`
11. `betaine-hcl`
12. `betaine-nitrate`
13. `boswellia-akba-standardized`
14. `catuaba`
15. `cordyceps-militaris`
16. `diosgenin`
17. `echinacoside`
18. `erinacines`
19. `garcinol`
20. `guggulsterone`
21. `inositol-hexanicotinate`
22. `maca-root-extract`
23. `macamides`
24. `oxyresveratrol`
25. `uc-ii-collagen`

## Structured trust changes

- Added 25 source-backed `runtime_safety` entries in Batch 2 and 50 across the pass.
- Labeled preclinical, regulatory, limited-human, formulation-specific, route-specific, and systematic-review evidence explicitly.
- Preserved constituent-versus-whole-extract and standalone-versus-combination-product boundaries.
- Kept medication interactions separate from contraindications.
- Used an explicit uncertainty statement when no evidence-backed contraindication is documented.
- Added provider guidance only when the published safety summary or interaction data supports a relevant topic.

## Evidence limitations

Many Batch 2 profiles concern isolated constituents whose available evidence comes from whole extracts, enriched products, topical use, multi-herb products, or laboratory and animal studies. Those findings were not presented as direct oral human safety guidance. Unsupported contraindications remain intentionally absent, and the page copy states that absence of a documented contraindication is not established safety.

The most evidence-limited profiles include isolated asarone, alpha-mangostin, atractylenolides, aucubin, erinacines, garcinol, macamides, oral oxyresveratrol, and the product-specific compound betaine nitrate.

## Audit improvement

| Metric | Before Trust Pass | After Batch 2 |
|---|---:|---:|
| Safety-reviewed profiles in scope | 50 | 50 |
| Trust-complete profiles | 0 | 50 |
| Profiles with reviewed runtime safety evidence | 0 | 50 |
| Remaining trust profiles | 50 | 0 |
| Trust validation errors | 0 | 0 |
| Remaining actionable safety gaps | 0 | 0 |

## Combined safety and trust completion totals

- Total compounds safety-reviewed: 50
- Total compounds updated during the safety pass: 45
- Total workbook safety cells revised during the safety pass: 89
- Evidence-supported safety entries added or materially improved: 53
- Unsupported token-only contraindications removed: 35
- Evidence-limited safety exceptions documented: 41
- Runtime safety evidence entries added during the trust pass: 50
- Profiles with evidence-strength labels: 50
- Remaining actionable safety gaps: 0
- Remaining trust-completeness profiles: 0

## Principal evidence

The two trust patch files contain complete titles, identifiers, confidence, and per-profile rationale. Batch 2 reused the completed safety review's systematic reviews, regulatory assessments, and human trials for Boswellia constituents, acemannan, asarone, alpha-mangostin, ashitaba, atractylenolides, aucubin, betaine HCl and nitrate, catuaba, Cordyceps militaris, diosgenin, echinacoside, erinacines, garcinol, guggulsterone, inositol hexanicotinate, maca and macamides, oxyresveratrol, and UC-II collagen.

## Validation

- Workbook patch validation: passed (25 Batch 2 changes; 50 total trust changes)
- Workbook schema validation: passed (881 rows, 52 columns)
- Workbook round-trip test: passed (22 sheets preserved)
- Core data build: passed
- Trust completeness audit: passed (50 complete, 0 remaining, 0 errors)
- Safety audit: passed (100% narrative safety context; 0 actionable full-public gaps)
- Source-of-truth guard: passed
- TypeScript: passed
- ESLint: passed with zero warnings
- Vitest: passed (97 files, 606 tests)
- Production static-export build: passed (20 deploy steps, 1,187 static pages)

## Recommended next priorities

1. Re-review the 41 evidence-limited exceptions when exact-formulation human safety evidence becomes available.
2. Extend the exception-aware trust audit to the next publication tier while preserving the same evidence standard.
3. Periodically verify that generated runtime safety remains identical to the workbook source of truth.
